Summit Financial Wealth Advisors, LLC Phathom Pharmaceuticals, Inc. Transaction History
Summit Financial Wealth Advisors, LLC
- $490 Million
- Q4 2024
A detailed history of Summit Financial Wealth Advisors, LLC transactions in Phathom Pharmaceuticals, Inc. stock. As of the latest transaction made, Summit Financial Wealth Advisors, LLC holds 68,125 shares of PHAT stock, worth $377,412. This represents 0.11% of its overall portfolio holdings.
Number of Shares
68,125
Previous 29,032
134.65%
Holding current value
$377,412
Previous $524,000
5.53%
% of portfolio
0.11%
Previous 0.1%
Shares
2 transactions
Others Institutions Holding PHAT
# of Institutions
158Shares Held
68.6MCall Options Held
52.3KPut Options Held
635K-
Frazier Life Sciences Management, L.P. Menlo Park, CA10.1MShares$56 Million4.92% of portfolio
-
Medicxi Ventures Management (Jersey) LTD7.46MShares$41.4 Million13.31% of portfolio
-
Jennison Associates LLC7.06MShares$39.1 Million0.04% of portfolio
-
Invesco Ltd. Atlanta, GA3.67MShares$20.3 Million0.01% of portfolio
-
Carlyle Group Inc. Washington, DC3.5MShares$19.4 Million28.4% of portfolio
About Phathom Pharmaceuticals, Inc.
- Ticker PHAT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,175,200
- Market Cap $217M
- Description
- Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also develo...